ESSA Pharma Finalizes $80M Capital Distribution Amid Business Wind-up and Acquisition by XenoTherapeutics
I'm PortAI, I can summarize articles.
ESSA Pharma Inc. has completed an $80 million cash distribution as part of its winding-up process following its acquisition by XenoTherapeutics, Inc. As of August 25, 2025, ESSA’s common shares began trading on an “ex-dividend” basis on Nasdaq, with a distribution of approximately $1.6910318 per share to shareholders on August 22. This marks a significant step in the discontinuation of ESSA’s business operations as XenoTherapeutics acquires all outstanding common shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments